[SCHEDULE 13G] SpringWorks Therapeutics, Inc. SEC Filing
Goldman Sachs Group, Inc. and its affiliate Goldman Sachs & Co. LLC report beneficial ownership of 4,234,033.35 shares of SpringWorks Therapeutics common stock, representing 5.6% of the class. The filing shows the positions are held with shared voting power (4,233,899.35 shares) and shared dispositive power (4,234,021.35 shares), and no sole voting or dispositive power is reported. The statement certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing includes a joint filing agreement and identifies Goldman Sachs & Co. LLC as a subsidiary of the parent reporting entity.
Goldman Sachs Group, Inc. e la sua affiliata Goldman Sachs & Co. LLC dichiarano la propriet脿 effettiva di 4,234,033.35 azioni ordinarie di SpringWorks Therapeutics, pari al 5.6% della classe. La comunicazione indica che le posizioni sono detenute con potere di voto condiviso (4,233,899.35 azioni) e potere di disposizione condiviso (4,234,021.35 azioni), e non viene riportato alcun potere di voto o di disposizione esclusivo. La dichiarazione certifica che i titoli sono stati acquisiti e sono detenuti nell'ordinaria attivit脿 d'impresa e non allo scopo di modificare o influenzare il controllo. Il deposito include un accordo di deposito congiunto e identifica Goldman Sachs & Co. LLC come controllata dell'entit脿 madre che effettua la segnalazione.
Goldman Sachs Group, Inc. y su filial Goldman Sachs & Co. LLC informan la propiedad beneficiaria de 4,234,033.35 acciones ordinarias de SpringWorks Therapeutics, que representan el 5.6% de la clase. La presentaci贸n muestra que las posiciones se mantienen con poder de voto compartido (4,233,899.35 acciones) y poder dispositvo compartido (4,234,021.35 acciones), y no se reporta ning煤n poder de voto o dispositvo exclusivo. La declaraci贸n certifica que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control. La presentaci贸n incluye un acuerdo de presentaci贸n conjunta e identifica a Goldman Sachs & Co. LLC como subsidiaria de la entidad matriz informante.
Goldman Sachs Group, Inc. 氚� 攴� 瓿勳棿靷� Goldman Sachs & Co. LLC電� SpringWorks Therapeutics 氤错喌欤� 4,234,033.35欤�(頃措嫻 韥措灅鞀れ潣 5.6%)鞚� 鞁れ唽鞙犽ゼ 氤搓碃頃╇媹雼�. 鞝滌稖靹滊鞐� 霐半ゴ氅� 氤挫湢 韽靺橃潃 瓿惦彊 鞚橁舶甓�(4,233,899.35欤�)瓿� 瓿惦彊 觳橂秳甓�(4,234,021.35欤�)鞙茧 氤搓碃霅橃棃鞙茧┌, 雼弲 鞚橁舶甓� 霕愲姅 雼弲 觳橂秳甓岇潃 氤搓碃霅橃 鞎婌晿鞀惦媹雼�. 靹彪獏鞚� 鞚� 歃濌秾霌れ澊 鞓侅梾鞚� 韱奠儊鞝侅澑 瓿检爼鞐愳劀 旆摑路氤挫湢霅� 瓴冹澊氅� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 氙胳箻旮� 鞙勴暅 氇╈爜鞚� 鞎勲媹霛缄碃 歃濍獏頃╇媹雼�. 鞝滌稖靹滊鞐愲姅 瓿惦彊 鞝滌稖 瓿勳暯鞚� 韽暔霅橃柎 鞛堦碃 Goldman Sachs & Co. LLC臧� 氤搓碃頃橂姅 氇殞靷� 靻岇湢鞚� 鞛愴殞靷 鞁濍硠霅橃柎 鞛堨姷雼堧嫟.
Goldman Sachs Group, Inc. et sa filiale Goldman Sachs & Co. LLC d茅clarent la propri茅t茅 b茅n茅ficiaire de 4,234,033.35 actions ordinaires de SpringWorks Therapeutics, repr茅sentant 5.6% de la cat茅gorie. Le dossier indique que les positions sont d茅tenues avec pouvoir de vote partag茅 (4,233,899.35 actions) et pouvoir de disposition partag茅 (4,234,021.35 actions), et qu'aucun pouvoir de vote ou de disposition exclusif n'est signal茅. La d茅claration certifie que les titres ont 茅t茅 acquis et sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le. Le d茅p么t comprend un accord de d茅p么t conjoint et identifie Goldman Sachs & Co. LLC comme filiale de la soci茅t茅 m猫re d茅clarante.
Goldman Sachs Group, Inc. und seine Tochtergesellschaft Goldman Sachs & Co. LLC melden wirtschaftliches Eigentum an 4,234,033.35 Aktien der SpringWorks Therapeutics-Stammaktien, was 5.6% der Klasse entspricht. Die Meldung zeigt, dass die Positionen mit gemeinsamen Stimmrechten (4,233,899.35 Aktien) und gemeinsamer Verf眉gungsmacht (4,234,021.35 Aktien) gehalten werden, und es werden keine alleinigen Stimm- oder Verf眉gungsbefugnisse angegeben. Die Erkl盲rung bescheinigt, dass die Wertpapiere im gew枚hnlichen Gesch盲ftsverkehr erworben und gehalten werden und nicht mit dem Ziel, die Kontrolle zu 盲ndern oder zu beeinflussen. Die Einreichung enth盲lt eine Vereinbarung 眉ber eine gemeinsame Einreichung und benennt Goldman Sachs & Co. LLC als Tochtergesellschaft des meldenden Mutterunternehmens.
- Material disclosure: The filing transparently reports 4,234,033.35 shares, crossing the 5% threshold and providing market clarity.
- Passive position: The Schedule 13G and certification state the holdings are held in the ordinary course of business and not to influence control.
- No sole voting or dispositive power: The reporting persons indicate 0 shares of sole voting or dispositive power, limiting direct governance influence.
- Concentrated stake: A single financial group holds 5.6% of the class, which increases ownership concentration even if passive.
Insights
TL;DR: Goldman Sachs reports a material passive stake of 5.6% in SpringWorks, disclosed as shared holdings without sole control.
The reported 4.23 million-share position equals 5.6% of SpringWorks' common stock, crossing the 5% reporting threshold and requiring public disclosure. The Schedule 13G presentation and the certification that the holdings are in the ordinary course indicate a passive, non-control position rather than an activist stake. For market participants, this clarifies ownership concentration and the role of a major financial institution as a significant shareholder, but it does not signal an intent to change management or strategy.
TL;DR: Reporting shows shared voting and dispositive authority, with no sole control; governance influence appears limited per the filing.
The filing discloses shared voting power and shared dispositive power with zero sole powers, which is material for governance analysis because sole voting authority is not claimed. The statement explicitly affirms the securities are not held to influence control, and the joint filing agreement clarifies coordination between the parent and its subsidiary. These facts suggest the reported position is relevant to ownership concentration but does not reflect an immediate governance change or control intent.
Goldman Sachs Group, Inc. e la sua affiliata Goldman Sachs & Co. LLC dichiarano la propriet脿 effettiva di 4,234,033.35 azioni ordinarie di SpringWorks Therapeutics, pari al 5.6% della classe. La comunicazione indica che le posizioni sono detenute con potere di voto condiviso (4,233,899.35 azioni) e potere di disposizione condiviso (4,234,021.35 azioni), e non viene riportato alcun potere di voto o di disposizione esclusivo. La dichiarazione certifica che i titoli sono stati acquisiti e sono detenuti nell'ordinaria attivit脿 d'impresa e non allo scopo di modificare o influenzare il controllo. Il deposito include un accordo di deposito congiunto e identifica Goldman Sachs & Co. LLC come controllata dell'entit脿 madre che effettua la segnalazione.
Goldman Sachs Group, Inc. y su filial Goldman Sachs & Co. LLC informan la propiedad beneficiaria de 4,234,033.35 acciones ordinarias de SpringWorks Therapeutics, que representan el 5.6% de la clase. La presentaci贸n muestra que las posiciones se mantienen con poder de voto compartido (4,233,899.35 acciones) y poder dispositvo compartido (4,234,021.35 acciones), y no se reporta ning煤n poder de voto o dispositvo exclusivo. La declaraci贸n certifica que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control. La presentaci贸n incluye un acuerdo de presentaci贸n conjunta e identifica a Goldman Sachs & Co. LLC como subsidiaria de la entidad matriz informante.
Goldman Sachs Group, Inc. 氚� 攴� 瓿勳棿靷� Goldman Sachs & Co. LLC電� SpringWorks Therapeutics 氤错喌欤� 4,234,033.35欤�(頃措嫻 韥措灅鞀れ潣 5.6%)鞚� 鞁れ唽鞙犽ゼ 氤搓碃頃╇媹雼�. 鞝滌稖靹滊鞐� 霐半ゴ氅� 氤挫湢 韽靺橃潃 瓿惦彊 鞚橁舶甓�(4,233,899.35欤�)瓿� 瓿惦彊 觳橂秳甓�(4,234,021.35欤�)鞙茧 氤搓碃霅橃棃鞙茧┌, 雼弲 鞚橁舶甓� 霕愲姅 雼弲 觳橂秳甓岇潃 氤搓碃霅橃 鞎婌晿鞀惦媹雼�. 靹彪獏鞚� 鞚� 歃濌秾霌れ澊 鞓侅梾鞚� 韱奠儊鞝侅澑 瓿检爼鞐愳劀 旆摑路氤挫湢霅� 瓴冹澊氅� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 氙胳箻旮� 鞙勴暅 氇╈爜鞚� 鞎勲媹霛缄碃 歃濍獏頃╇媹雼�. 鞝滌稖靹滊鞐愲姅 瓿惦彊 鞝滌稖 瓿勳暯鞚� 韽暔霅橃柎 鞛堦碃 Goldman Sachs & Co. LLC臧� 氤搓碃頃橂姅 氇殞靷� 靻岇湢鞚� 鞛愴殞靷 鞁濍硠霅橃柎 鞛堨姷雼堧嫟.
Goldman Sachs Group, Inc. et sa filiale Goldman Sachs & Co. LLC d茅clarent la propri茅t茅 b茅n茅ficiaire de 4,234,033.35 actions ordinaires de SpringWorks Therapeutics, repr茅sentant 5.6% de la cat茅gorie. Le dossier indique que les positions sont d茅tenues avec pouvoir de vote partag茅 (4,233,899.35 actions) et pouvoir de disposition partag茅 (4,234,021.35 actions), et qu'aucun pouvoir de vote ou de disposition exclusif n'est signal茅. La d茅claration certifie que les titres ont 茅t茅 acquis et sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le. Le d茅p么t comprend un accord de d茅p么t conjoint et identifie Goldman Sachs & Co. LLC comme filiale de la soci茅t茅 m猫re d茅clarante.
Goldman Sachs Group, Inc. und seine Tochtergesellschaft Goldman Sachs & Co. LLC melden wirtschaftliches Eigentum an 4,234,033.35 Aktien der SpringWorks Therapeutics-Stammaktien, was 5.6% der Klasse entspricht. Die Meldung zeigt, dass die Positionen mit gemeinsamen Stimmrechten (4,233,899.35 Aktien) und gemeinsamer Verf眉gungsmacht (4,234,021.35 Aktien) gehalten werden, und es werden keine alleinigen Stimm- oder Verf眉gungsbefugnisse angegeben. Die Erkl盲rung bescheinigt, dass die Wertpapiere im gew枚hnlichen Gesch盲ftsverkehr erworben und gehalten werden und nicht mit dem Ziel, die Kontrolle zu 盲ndern oder zu beeinflussen. Die Einreichung enth盲lt eine Vereinbarung 眉ber eine gemeinsame Einreichung und benennt Goldman Sachs & Co. LLC als Tochtergesellschaft des meldenden Mutterunternehmens.
FAQ
Who filed the Schedule 13G for SpringWorks Therapeutics (SWTX)?
How many SpringWorks (SWTX) shares does Goldman Sachs report owning?
What percentage of SpringWorks (SWTX) does that stake represent?
Does Goldman Sachs claim sole voting or dispositive power over these shares?
Does the Schedule 13G indicate intent to influence control of SpringWorks?
